Biopharma & Life Sciences
Corcept Therapeutics Executive Compensation (FY25)
CORT · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Joseph Belanoff | Latest say-on-pay support = May 21, 2026 | Chief executive pay ratio ◇ To the median employee |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The Corcept Therapeutics brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Data as of November 5, 2026Latest filing (8-K): May 28, 2026
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
278 figures on this page: 272 cited to the filing that reported them, 6 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Joseph Belanoff: $9,890,081 → $15,303,551 (54.7% higher)
Say-on-pay support: 94.6% → 94.1% (0.5 points lower)
CEO pay ratio: 40:1 → 46:1 (15.0% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Corcept Therapeutics' chief executive and what were they paid?
Total compensation for Joseph Belanoff, Chief Executive Officer and President, came to $15,303,551 in fiscal 2025. Belanoff's total moved 54.7% higher from the $9,890,081 reported for fiscal 2024.
What was Corcept Therapeutics' say-on-pay result?
The say-on-pay proposal drew 94.1% of votes cast for or against in favor at the meeting held May 21, 2026 for fiscal 2025.
What is Corcept Therapeutics' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 46:1, against median employee compensation of $334,040.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Joseph Belanoff Chief Executive Officer and President | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Sean Maduck President, Corcept Endocrinology | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Charles Robb Chief Business Officer and Secretary | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Pharm.D. William Guyer Chief Development Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Atabak Mokari Chief Financial Officer and Treasurer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Joseph Belanoff Chief Executive Officer and President | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Charles Robb Chief Business Officer and Secretary | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Sean Maduck President, Corcept Endocrinology | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
William Pharm.D. Chief Development Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
William Guyer Chief Development Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Atabak Mokari Chief Financial Officer and Treasurer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Joseph Belanoff Chief Executive Officer and President | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Charles Robb Chief Business Officer and Secretary | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Pharm.D. William Guyer Chief Development Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Sean Maduck President Corcept Endocrinology | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Atabak Mokari Chief Financial Officer and Treasurer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Joseph Belanoff Chief Executive Officer and President | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Charles Robb Chief Business Officer and Secretary | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
William Guyer Chief Development Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Sean Maduck President, Corcept Endocrinology | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Atabak Mokari Chief Financial Officer and Treasurer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Atabak Mokari | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Charles Robb | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Joseph K. Belanoff | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Sean Maduck | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| William Guyer | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Joseph Belanoff | Option | ◇ | — | ◇ | 2/28/2035 |
| Option | ◇ | — | ◇ | 2/9/2034 | |
| Option | ◇ | — | ◇ | 2/13/2033 | |
| Option | ◇ | — | ◇ | 2/2/2032 | |
| Charles Robb | Option | ◇ | — | ◇ | 2/28/2035 |
| Option | ◇ | — | ◇ | 2/9/2034 | |
| Option | ◇ | — | ◇ | 2/13/2033 | |
| Option | ◇ | — | ◇ | 2/2/2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Atabak Mokari | Option | ◇ | — | ◇ | 2/28/2035 |
| Option | ◇ | — | ◇ | 2/9/2034 | |
| Option | ◇ | — | ◇ | 2/13/2033 | |
| Option | ◇ | — | ◇ | 2/2/2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Sean Maduck | Option | ◇ | — | ◇ | 2/28/2035 |
| Option | ◇ | — | ◇ | 2/9/2034 | |
| Option | ◇ | — | ◇ | 2/13/2033 | |
| Option | ◇ | — | ◇ | 2/2/2032 | |
| Option | ◇ | — | ◇ | 5/2/2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| William Guyer | Option | ◇ | — | ◇ | 2/28/2035 |
| Option | ◇ | — | ◇ | 2/9/2034 | |
| Option | ◇ | — | ◇ | 2/13/2033 | |
| Option | ◇ | — | ◇ | 2/2/2032 | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Charles Robb
Chief Business Officer and Secretary · Change-in-control agreement
| Change-in-control multiple | ◇ |
Sean Maduck
President, Corcept Endocrinology · Change-in-control agreement
| Severance multiple | ◇ |
| Severance base | ◇ |
| Change-in-control multiple | ◇ |
| Change-in-control base | ◇ |
| Benefits continuation on change in control | ◇ |
| Benefits continuation | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
James N. Wilson Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Gregg Alton | ◇ | — | ◇ | — | — | — | ◇ |
David L. Mahoney | ◇ | — | ◇ | — | — | — | ◇ |
Gillian M. Cannon | ◇ | — | ◇ | — | — | ◇ | ◇ |
G. Leonard Baker Jr | ◇ | — | ◇ | — | — | — | ◇ |
Kimberly Park | ◇ | — | ◇ | — | — | — | ◇ |
Joshua M. Murray | ◇ | — | ◇ | — | — | — | ◇ |
Daniel N. Swisher Jr | ◇ | — | ◇ | — | — | — | ◇ |
Joseph K. Belanoff served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 21, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 10, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 17, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 19, 2023 | = | ◇ | ◇ | ◇ |
| 2019 | May 27, 2020 | = | ◇ | ◇ | ◇ |
| 2016 | May 24, 2017 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Joseph Belanoff (Chief Executive Officer and President), FY2025 total compensation $15,303,551 (base salary $1,182,333) [exec_comp, SEC accession 0001628280-26-025735, filed 2026-04-17]What this page does not include
Everything above is a fact Corcept Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
278 figures on this page: 272 cited to the filing that reported them, 6 calculated from figures it prints.
272 cited to the filing
6 calculated from the filing
Documents cited
- 0001628280-26-038793Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-26-025735CEO Pay Ratio · DIRECTOR COMPENSATION · Grants of Plan-Based Awards · Potential Payments Upon Termination
- 0001628280-25-031624Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-25-019942
- 0001628280-24-024936Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-23-019588
- 0001628280-20-008606Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-17-187378
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Corcept Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/CORT (accessed 2026).
Short form: data: Velarion
The Corcept Therapeutics brief, $500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Corcept Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}